2-(氯甲基)-1-吡咯烷甲酸叔丁酯 | 1142400-61-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 2-(氯甲基)-1-吡咯烷甲酸叔丁酯
• 英文名称: tert-Butyl 2-(chloromethyl)pyrrolidine-1-carboxylate
• CAS: 1142400-61-0
• 化学式: C₁₀H₁₈ClNO₂
• 分子量: 219.71
• InChiKey: KTDOGEILJSFSSG-UHFFFAOYSA-N

物化性质

• 沸点：
  284℃
• 密度：
  1.101
• 闪点：
  126℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D]PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP3470415A1

  公开（公告）日：2019-04-17

  The present invention provides a compound comprising a 5-membered heterocycle fused with a pyridazinone, wherein the compound is used as an FGFR kinase inhibitor, and a manufacturing method and application thereof. The invention specifically provides a compound as represented by formula (I). Various radicals are as defined in the specification. The compound provided by the invention effectively inhibits an activity of an FGFR kinase, and can be used to manufacture a pharmaceutical product for treating a disease related to the activity of the FGFR kinase.

  本发明提供了一种化合物，该化合物包括与吡啶并嗪酮融合的5-成员杂环，其中该化合物用作FGFR激酶抑制剂，以及其制备方法和应用。该发明具体提供了一种由式（I）表示的化合物。各种基团如规范中所定义。本发明提供的化合物有效抑制FGFR激酶的活性，并可用于制造用于治疗与FGFR激酶活性相关的疾病的药物产品。
• 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D] PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：US20190135818A1

  公开（公告）日：2019-05-09

  The present invention provides a compound comprising a 5-membered heterocycle fused with a pyridazinone, wherein the compound is used as an FGFR kinase inhibitor, and a manufacturing method and application thereof. The invention specifically provides a compound as represented by formula (I). Various radicals are as defined in the specification. The compound provided by the invention effectively inhibits an activity of an FGFR kinase, and can be used to manufacture a pharmaceutical product for treating a disease related to the activity of the FGFR kinase.